Breaking News Instant updates and real-time market news.

AXON

Axovant Sciences

$13.45

-0.03 (-0.22%)

, LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

07:20
11/23/16
11/23
07:20
11/23/16
07:20

Axovant Sciences drops 18% after Lilly Alzheimer's study failure

Axovant (AXON) is developing its own drug for the treatment of patients with Alzheimer's disease. As previously reported, Eli Lilly (LLY) announced earlier that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease.

AXON

Axovant Sciences

$13.45

-0.03 (-0.22%)

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

  • 29

    Nov

  • 04

    Dec

AXON Axovant Sciences
$13.45

-0.03 (-0.22%)

09/22/16
JMPS
09/22/16
NO CHANGE
JMPS
Axovant Sciences weakness an opportunity, says JMP Securities
09/22/16
CHDN
09/22/16
NO CHANGE
Target $8
CHDN
Sell
Recent failures of 5-HT6 competitors reinforce Axovant risks, says Chardan
After Lundbeck reported that its 5-HT6 antagonist, idalopirdine, did not meet the primary endpoint in the first of three phase III studies in mild-to-moderate Alzheimer's disease patients, Chardan analyst Gbola Amusa noted that this is the second recent failure of a mid-to-late-stage 5-HT6 antagonist coming on the heels of Pfizer's (PFE) prior miss. Amusa anticipates that some in the market will see limited read-across from Lundbeck to Axovant (AXON), but he thinks Pfizer's and Lundbeck's setbacks reinforce the risks for the 5-HT6 antagonist class in Alzheimer's. The analyst reiterates his Sell rating and $8 price target on Axovant shares.
09/22/16
HCWC
09/22/16
NO CHANGE
Target $35
HCWC
Buy
No read-through from idalopirdine to Axovant RVT-101, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein notes that Lundbeck announced that its idalopirdine missed its primary and secondary endpoints in the STARSHINE Phase 3 study in mild/moderate Alzheimer's disease. However, Fein says that idalopirdine miss does not shake his confidence in Axovant's RVT-101 as he believes Lundbeck may have simply not been able to dose idalopirdine high enough in the Phase 3 program, which minimizes read-through to Axovant's MINDSET Phase 3 study. He continues to believe that Axovant's own experimental Alzheimer's therapy is well positioned for a win. Fein reiterates a Buy rating and $35 price target on Axovant's shares. In afternoon trading, Axovant's stock has dropped almost 12% to $15.31 per share.
09/23/16
PIPR
09/23/16
NO CHANGE
Target $32
PIPR
Overweight
Axovant Sciences selloff provides entry point, says Piper Jaffray
Piper Jaffray analyst Charles Duncan believes yesterday's selloff in shares of Axovant Sciences provides an entry point into the name. Lundbeck's announcement that its first Phase III data with idalopirdine in Alzheimer's missed the primary endpoint does not have predictive value for the Axovant's ongoing RVT-101 Phase III study, Duncan tells investors in a research note. The analyst sees "several key differences" between the two candidates and Phase III programs. He believes RVT-101 is the best-in-class 5-HT6 candidate and thinks its MINDSET trial is well designed to show clinical benefit. Duncan reiterates an Overweight rating on Axovant with a $32 price target.
LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Neutral
Citi pegs potential Biogen downside to $287 on Lilly failure
In a research note dated yesterday, Citi analyst Robyn Karnauskas said shares of Biogen (BIIB) could fall to $286 should Eli Lilly's (LLY) Alzheimer's drug solanezumab fail in its Phase 3 study. After Lilly reported this morning that the trial failed, shares of Biogen are down 6%, or $18.60, to $299.51 in pre-market trading. Shares of Lilly are down 14%, or $10.77, to $65.22. Karnauskas estimated the downside range of Biogen on a failed solanezumab study at $287-$306. The analyst has a Neutral rating on Biogen.

TODAY'S FREE FLY STORIES

ARQL

ArQule

$1.17

0.03 (2.63%)

, NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

04:55
06/25/17
06/25
04:55
06/25/17
04:55
Conference/Events
European Hematology Association to hold a conference »

22nd Congress of the EHA…

ARQL

ArQule

$1.17

0.03 (2.63%)

NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

BLUE

bluebird bio

$112.00

-6.5 (-5.49%)

XLRN

Acceleron

$34.10

0.15 (0.44%)

BLCM

Bellicum Pharmaceuticals

$13.39

-0.59 (-4.22%)

CRSP

CRISPR Therapeutics

$16.44

0.3 (1.86%)

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

STML

Stemline

$9.10

0.6 (7.06%)

CTIX

Cellceutix

KPTI

Karyopharm

$9.97

0.01 (0.10%)

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

CDTX

Cidara Therapeutics

$6.70

-0.2 (-2.90%)

GBT

Global Blood Therapeutics

$29.85

0.6 (2.05%)

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

TGTX

TG Therapeutics

$11.95

-0.05 (-0.42%)

VSTM

Verastem

$2.32

-0.06 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 11

    Jul

  • 26

    Sep

HIMX

Himax

$8.17

-0.02 (-0.24%)

04:55
06/25/17
06/25
04:55
06/25/17
04:55
Conference/Events
Himax management to meet with Roth Captial »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

13:47
06/24/17
06/24
13:47
06/24/17
13:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$146.28

0.65 (0.45%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

IBM

IBM

$154.11

-0.29 (-0.19%)

MA

MasterCard

$124.01

0.71 (0.58%)

ORCL

Oracle

$50.95

0.65 (1.29%)

VMW

VMware

$90.92

0.48 (0.53%)

INTC

Intel

$34.19

-0.17 (-0.49%)

AKAM

Akamai

$51.30

1.28 (2.56%)

SAP

SAP

$107.48

0.42 (0.39%)

QCOM

Qualcomm

$56.91

0.44 (0.78%)

ADBE

Adobe

$145.41

1.72 (1.20%)

ACN

Accenture

$122.74

0.66 (0.54%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

LPNT

LifePoint

$65.50

-1.6 (-2.38%)

CYH

Community Health

$9.33

0.06 (0.65%)

THC

Tenet

$18.52

-0.38 (-2.01%)

HCA

HCA Holdings

$86.24

0.1 (0.12%)

UHS

Universal Health

$115.43

0.22 (0.19%)

AET

Aetna

$152.10

-0.88 (-0.58%)

WCG

WellCare

$183.28

-0.32 (-0.17%)

CI

Cigna

$169.61

-1.07 (-0.63%)

HUM

Humana

$238.42

1.42 (0.60%)

ANTM

Anthem

$190.17

-3.19 (-1.65%)

HNT

Health Net

CNC

Centene

$84.15

1.15 (1.39%)

MOH

Molina Healthcare

$71.33

0.02 (0.03%)

UNH

UnitedHealth

$185.25

-1.25 (-0.67%)

REGN

Regeneron

$517.33

-9.2 (-1.75%)

CELG

Celgene

$134.31

0.63 (0.47%)

VRTX

Vertex

$133.50

-2.03 (-1.50%)

ALXN

Alexion

$126.07

-0.16 (-0.13%)

BIIB

Biogen

$280.32

-0.25 (-0.09%)

AMGN

Amgen

$172.50

-1.32 (-0.76%)

X

U.S. Steel

$22.25

1.18 (5.60%)

AKS

AK Steel

$6.65

0.35 (5.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 06

    Jul

  • 12

    Jul

  • 13

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 02

    Aug

  • 14

    Aug

  • 23

    Oct

  • 03

    Feb

ARQL

ArQule

$1.17

0.03 (2.63%)

, NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
European Hematology Association to hold a conference »

22nd Congress of the EHA…

ARQL

ArQule

$1.17

0.03 (2.63%)

NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

BLUE

bluebird bio

$112.00

-6.5 (-5.49%)

XLRN

Acceleron

$34.10

0.15 (0.44%)

BLCM

Bellicum Pharmaceuticals

$13.39

-0.59 (-4.22%)

CRSP

CRISPR Therapeutics

$16.44

0.3 (1.86%)

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

STML

Stemline

$9.10

0.6 (7.06%)

CTIX

Cellceutix

KPTI

Karyopharm

$9.97

0.01 (0.10%)

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

CDTX

Cidara Therapeutics

$6.70

-0.2 (-2.90%)

GBT

Global Blood Therapeutics

$29.85

0.6 (2.05%)

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

TGTX

TG Therapeutics

$11.95

-0.05 (-0.42%)

VSTM

Verastem

$2.32

-0.06 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 27

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 11

    Jul

  • 26

    Sep

HIMX

Himax

$8.17

-0.02 (-0.24%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
Himax management to meet with Roth Captial »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

ANTM

Anthem

$190.17

-3.19 (-1.65%)

18:58
06/23/17
06/23
18:58
06/23/17
18:58
Periodicals
Anthem to pay $115M to settle data breach lawsuits, Reuters reports »

Anthem has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVU

Supervalu

$2.94

-0.04 (-1.34%)

18:26
06/23/17
06/23
18:26
06/23/17
18:26
Hot Stocks
Supervalu completes acquisition of Unified Grocers »

Supervalu announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$70.52

0.04 (0.06%)

18:14
06/23/17
06/23
18:14
06/23/17
18:14
Periodicals
Gilead no longer a 'value trap,' Barron's reports »

Consistent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

SONA

Southern National Bancorp

$17.21

0.11 (0.64%)

, EVBS

Eastern Virginia Bankshares

$11.01

0.14 (1.29%)

18:07
06/23/17
06/23
18:07
06/23/17
18:07
Hot Stocks
Southern National Bancorp, Eastern Virginia Bankshares complete merger »

Southern National Bancorp…

SONA

Southern National Bancorp

$17.21

0.11 (0.64%)

EVBS

Eastern Virginia Bankshares

$11.01

0.14 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAC

IAC

$104.84

0.3 (0.29%)

17:56
06/23/17
06/23
17:56
06/23/17
17:56
Hot Stocks
IAC will not pursue plan to create new class of non-voting stock »

IAC's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

EGL

Engility

$27.37

0.26 (0.96%)

17:50
06/23/17
06/23
17:50
06/23/17
17:50
Hot Stocks
Engility to eliminate position of president, COO »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

ADM

Archer Daniels

$41.16

0.13 (0.32%)

17:48
06/23/17
06/23
17:48
06/23/17
17:48
Hot Stocks
ADM Animal Nutrition recalls Rough-N-Ready cattle feed over monensin concerns »

ADM Animal Nutrition, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOYA

Voya Financial

$35.24

0.03 (0.09%)

17:30
06/23/17
06/23
17:30
06/23/17
17:30
Syndicate
Breaking Syndicate news story on Voya Financial »

Voya Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBTX

Independent Bank

$54.85

-1.1 (-1.97%)

, TBK

Triumph Bancorp

17:19
06/23/17
06/23
17:19
06/23/17
17:19
Hot Stocks
Independent Bank to sell nine Colorado branches to TBK Bank »

Independent Bank (IBTX)…

IBTX

Independent Bank

$54.85

-1.1 (-1.97%)

TBK

Triumph Bancorp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

WUBA

58.com

$43.30

0.87 (2.05%)

17:11
06/23/17
06/23
17:11
06/23/17
17:11
Hot Stocks
Breaking Hot Stocks news story on 58.com »

General Atlantic reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

, LGF.B

Lionsgate

$25.38

0.34 (1.36%)

17:10
06/23/17
06/23
17:10
06/23/17
17:10
Hot Stocks
Box Office Battle: 'Transformers' expected to top 'Cars 3,' 'Wonder Woman' »

Viacom (VIA, VIAB)…

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

DIS

Disney

$104.36

0.14 (0.13%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

VIA

Viacom

$39.15

0.1 (0.26%)

SNE

Sony

$38.52

0.11 (0.29%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

TWX

Time Warner

$99.70

0.3 (0.30%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

NVUS

Novus Therapeutics

$6.00

-0.04 (-0.66%)

17:07
06/23/17
06/23
17:07
06/23/17
17:07
Syndicate
Breaking Syndicate news story on Novus Therapeutics  »

Novus Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDXG

Interpace Diagnostics

$0.88

0.03 (3.53%)

17:05
06/23/17
06/23
17:05
06/23/17
17:05
Hot Stocks
Breaking Hot Stocks news story on Interpace Diagnostics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$14.95

0.26 (1.77%)

17:02
06/23/17
06/23
17:02
06/23/17
17:02
Hot Stocks
Monmouth Real Estate acquires building in Texas for $50.6M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

ARCW

ARC Group

$3.55

0.15 (4.41%)

17:01
06/23/17
06/23
17:01
06/23/17
17:01
Hot Stocks
ARC Group names Drew Kelley as Interim CEO, effective July 1 »

ARC Group Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAVM

PAVmed

$4.41

-0.08 (-1.78%)

16:55
06/23/17
06/23
16:55
06/23/17
16:55
Syndicate
PAVmed announces effectiveness of Form S-1 resale registration statement »

PAVmed announced that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFSF

MutualFirst Financial

$36.15

0.9 (2.55%)

16:48
06/23/17
06/23
16:48
06/23/17
16:48
Hot Stocks
MutualFirst Financial senior executives enter 10b5-1 trading plans »

On June 23, David Heeter,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$32.10

0.25 (0.78%)

16:46
06/23/17
06/23
16:46
06/23/17
16:46
Hot Stocks
Cisco CEO Charles Robbins enters 10b5-1 trading plan »

On June 21, Charles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 12

    Jul

  • 12

    Jul

  • 13

    Jul

  • 16

    Aug

SITO

SITO Mobile

$3.66

0.02 (0.55%)

16:43
06/23/17
06/23
16:43
06/23/17
16:43
Hot Stocks
SITO Mobile chairman Paul Pressler resigns »

Effective as of June 23,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$517.33

-9.2 (-1.75%)

, CELG

Celgene

$134.31

0.63 (0.47%)

16:41
06/23/17
06/23
16:41
06/23/17
16:41
General news
S&P sees mild weekly gain, Nasdaq outperforms as biotech shines »

The S&P finished the…

REGN

Regeneron

$517.33

-9.2 (-1.75%)

CELG

Celgene

$134.31

0.63 (0.47%)

GILD

Gilead

$70.54

0.06 (0.09%)

BIIB

Biogen

$280.32

-0.25 (-0.09%)

VRTX

Vertex

$133.50

-2.03 (-1.50%)

AMGN

Amgen

$172.50

-1.32 (-0.76%)

ABBV

AbbVie

$72.64

-0.54 (-0.74%)

ALXN

Alexion

$126.07

-0.16 (-0.13%)

BA

Boeing

$202.23

2.79 (1.40%)

ORCL

Oracle

$50.95

0.65 (1.29%)

EQT

EQT Corporation

$56.19

4.16 (8.00%)

RICE

Rice Energy

$25.65

1.62 (6.74%)

SYK

Stryker

$141.12

-0.1 (-0.07%)

NVDQ

Novadaq

$11.78

-0.02 (-0.17%)

PRXL

Parexel

$86.80

-0.31 (-0.36%)

LH

LabCorp

$151.62

1.28 (0.85%)

ICLR

ICON plc

$96.37

-0.26 (-0.27%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

INTC

Intel

$34.19

-0.17 (-0.49%)

AMD

AMD

$14.15

-0.23 (-1.60%)

LZB

La-Z-Boy

$32.30

0.7 (2.22%)

RHT

Red Hat

$99.42

0.54 (0.55%)

AAL

American Airlines

$48.63

-0.34 (-0.69%)

HCA

HCA Holdings

$86.24

0.1 (0.12%)

LPNT

LifePoint

$65.50

-1.6 (-2.38%)

THC

Tenet

$18.52

-0.38 (-2.01%)

SCS

Steelcase

$13.65

-0.45 (-3.19%)

ACN

Accenture

$122.74

0.66 (0.54%)

BBBY

Bed Bath & Beyond

$29.65

-4.09 (-12.12%)

BBRY

BlackBerry

$9.71

-1.35 (-12.21%)

BAC

Bank of America

$22.82

-0.11 (-0.48%)

C

Citi

$63.41

-0.21 (-0.33%)

GS

Goldman Sachs

$217.19

-2.58 (-1.17%)

JPM

JPMorgan

$86.86

-0.16 (-0.18%)

MS

Morgan Stanley

$43.69

-0.92 (-2.06%)

WFC

Wells Fargo

$52.45

-0.04 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 23

    Jun

  • 26

    Jun

  • 26

    Jun

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 07

    Jul

  • 13

    Jul

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 14

    Aug

  • 29

    Aug

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 23

    Oct

  • 14

    Nov

  • 15

    Jan

  • 03

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.